Skip to Content
Merck
All Photos(1)

Documents

SML2918

Sigma-Aldrich

INT131

≥98% (HPLC)

Synonym(s):

2,4-Dichloro-N-[3,5-dichloro-4-(3-quinolinyloxy)phenyl]benzenesulfonamide, AMG-131, T0903131

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H12Cl4N2O3S
CAS Number:
315224-26-1
Molecular Weight:
514.21
MDL number:
MFCD13152369
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

InChI

1S/C21H12Cl4N2O3S/c22-13-5-6-20(16(23)8-13)31(28,29)27-14-9-17(24)21(18(25)10-14)30-15-7-12-3-1-2-4-19(12)26-11-15/h1-11,27H

InChI key

NMRWDFUZLLQSBN-UHFFFAOYSA-N

Biochem/physiol Actions

INT131 is a brain penetrant, non-thiazolidinedione, highly potent and selective peroxisome proliferator-activated receptor gamma (PPARγ) modulator (SPPARM) that displays anti-diabetic activities. INT131 is a partial, rather than a full agonist of PPARγ, and in clinical trials has shown increased glucose tolerance without the weight gain and cardiovascular side effects seen with some of the full agonist.

Storage Class Code

11 - Combustible Solids

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Xinni Xie et al.
Frontiers in pharmacology, 8, 317-317 (2017-06-15)
The mechanisms underlying the enhancement of insulin sensitivity by selective peroxisome proliferator-activated receptor γ modulators (sPPARγMs) are still not completely known. Here, the representative sPPARγM, INT131, was used as a probe to investigate the insulin-sensitizing mechanisms of sPPARγM in the
INT131: a selective modulator of PPAR gamma
Motani A, Wang Z, Weiszmann J, McGee LR, Lee G, Liu Q, Staunton J, Fang Z, Fuentes H, et al
Journal of Molecular Biology, 386, 1301-1311 (2009)
Amila Omeragic et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 34(2), 1996-2010 (2020-01-08)
Despite the use of antiretroviral therapy for the treatment of HIV-1 infection, cognitive impairments, that is, HIV-1-associated neurocognitive disorders remain prevalent potentially due to persistent viral replication, production of viral proteins, associated brain inflammation or in certain instances, antiretroviral neurotoxicity.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service